Certara (NASDAQ:CERT) Reaches New 1-Year Low – Time to Sell?

Certara, Inc. (NASDAQ:CERT) shares reached a new 52-week low during trading on Monday . The company traded as low as $7.10 and last traded at $7.0960, with a volume of 49251 shares changing hands. The stock had previously closed at $7.23.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CERT. Morgan Stanley cut their target price on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, December 18th. BMO Capital Markets assumed coverage on shares of Certara in a report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price target for the company. Barclays reduced their price objective on shares of Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a research note on Monday, December 15th. Leerink Partners upgraded shares of Certara from a “market perform” rating to an “outperform” rating and set a $13.00 target price on the stock in a research report on Tuesday, January 6th. Finally, Rothschild & Co Redburn set a $10.00 price target on Certara in a report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Certara has an average rating of “Moderate Buy” and an average target price of $12.82.

Certara Stock Down 2.4%

The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of 100.00 and a beta of 1.47. The firm’s 50-day moving average is $8.98 and its 200 day moving average is $10.22.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new stake in Certara during the first quarter worth about $259,000. Goldman Sachs Group Inc. increased its position in Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after purchasing an additional 90,724 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Certara by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after buying an additional 35,954 shares during the period. Jane Street Group LLC lifted its position in Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after buying an additional 40,463 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its position in Certara by 25.3% during the second quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock valued at $66,391,000 after buying an additional 1,145,554 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.